Ipilimumab, is a monoclonal antibody used in cancer immunotherapy. Here are some key points about ipilimumab:
Mechanism of Action: Ipilimumab works by targeting the CTLA-4 protein on T-cells, enhancing the immune system’s ability to attack cancer cells12.
Indications: It is used to treat various cancers, including:
Melanoma: Both metastatic and as an adjuvant therapy to prevent recurrence after surgery23.
Renal Cell Carcinoma: Often in combination with nivolumab2.
Colorectal Cancer: Particularly in cases with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors2.
Non-Small Cell Lung Cancer (NSCLC): In combination with nivolumab and other chemotherapy medications2.
Hepatocellular Carcinoma: Used in combination with nivolumab2.
Malignant Pleural Mesothelioma: In combination with nivolumab2.
Esophageal Cancer: In combination with nivolumab2.
Administration: Ipilimumab is administered as an intravenous infusion, typically over 30 to 90 minutes, depending on the specific treatment regimen23.
Side Effects: Common side effects include fatigue, diarrhea, skin rash, and colitis. Serious side effects can include severe immune-mediated reactions affecting various organs13.
Given your interest in biosimilars and monoclonal antibodies, ipilimumab is a significant example of how immunotherapy can be used to treat various types of cancer. If you need more detailed information or have specific questions, feel free to ask!